Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

J Med Chem. 2009 Oct 22;52(20):6201-4. doi: 10.1021/jm900951n.

Abstract

The prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose reabsorption in vivo.

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / urine
  • Drug Discovery
  • Glucose / metabolism
  • Humans
  • Mice
  • Sodium-Glucose Transporter 2 Inhibitors*
  • Substrate Specificity
  • Xylose / administration & dosage
  • Xylose / analogs & derivatives*
  • Xylose / pharmacology*
  • Xylose / therapeutic use

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Xylose
  • Glucose